
Vignesh Packiam/X
Apr 23, 2025, 10:35
Vignesh Packiam: I am generally aggressive in promoting bladder sparing for NMIBC
Vignesh Packiam, Associate Professor at Rutgers Cancer Institute of New Jersey, shared a post by Sia Daneshmand, Urologic Oncology Fellowship Director at University of Southern California, adding:
“LVI is tough. With our improved management and therapies I am generally aggressive in promoting bladder sparing for NMIBC – but this gives pause: T1 with LVI had higher node positivity rates than MIBC without LVI, at least in NCDB 2004-2014.”

Quoting Sia Daneshmand‘s post:
“Couldn’t agree more. Leilei Xia found similar results in updated cohort 2010-2018 cT1 + LVI compared to T2 w/o LVI associated with significantly worse OS HR 1.63.”
Authors: Ryan P Werntz, Zachary L Smith, Vignesh T Packiam, Norm Smith, Gary D Steinberg

-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 23, 2025, 10:33
Apr 23, 2025, 10:15
Apr 23, 2025, 10:12
Apr 23, 2025, 10:05
Apr 23, 2025, 08:35